India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Amifampridine Tablets, 10 mg.
Amifampridine Tablets, 10 mg, are bioequivalent to the reference listed drug, Firdapse Tablets, 10 mg, from Catalyst Pharmaceuticals Inc, for the indication in the approved labeling. Firdapse Tablets are indicated for people aged 6 years and older living with Lambert-Eaton myasthenic syndrome (LEMS), to help maintain muscle strength and mobility.
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity.
Lupin's Amifampridine Tablets approved by US FDA
Roche wins FDA clearance for customisable respiratory pathogen test
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Immunome secures EMA validation of varegacestat application for desmoid tumors
Celularity and Vesalius sign exclusive US peptide manufacturing agreement
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
United Therapeutics receives FDA clearance to advance inhaled PAH therapy into clinical trials